Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $662 | $608 | $667 | $580 |
| % Growth | 8.9% | -8.9% | 15.1% | – |
| Cost of Goods Sold | $78 | $84 | $87 | $75 |
| Gross Profit | $584 | $524 | $580 | $505 |
| % Margin | 88.2% | 86.2% | 86.9% | 87.1% |
| R&D Expenses | $109 | $92 | $75 | $90 |
| G&A Expenses | $247 | $237 | $109 | $105 |
| SG&A Expenses | $336 | $336 | $377 | $305 |
| Sales & Mktg Exp. | $89 | $100 | $268 | $200 |
| Other Operating Expenses | $58 | $101 | $82 | $23 |
| Operating Expenses | $502 | $529 | $534 | $419 |
| Operating Income | $82 | -$5 | $46 | $86 |
| % Margin | 12.3% | -0.9% | 6.9% | 14.8% |
| Other Income/Exp. Net | $16 | $8 | $15 | -$13 |
| Pre-Tax Income | $98 | $3 | $61 | $73 |
| Tax Expense | $24 | $1 | $0 | $20 |
| Net Income | $74 | $1 | $61 | $53 |
| % Margin | 11.2% | 0.2% | 9.1% | 9.2% |
| EPS | 1.34 | 0.024 | 1.13 | 1.01 |
| % Growth | 5,460.2% | -97.9% | 11.9% | – |
| EPS Diluted | 1.32 | 0.024 | 1.04 | 0.98 |
| Weighted Avg Shares Out | 55 | 55 | 54 | 53 |
| Weighted Avg Shares Out Dil | 56 | 56 | 62 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $10 | $22 | $11 |
| Interest Expense | $0 | $2 | $7 | $23 |
| Depreciation & Amortization | $80 | $85 | $86 | $33 |
| EBITDA | $178 | $90 | $153 | $129 |
| % Margin | 26.9% | 14.8% | 23% | 22.3% |